logo
Study from Pittsburgh researchers detects invisible diabetic wounds

Study from Pittsburgh researchers detects invisible diabetic wounds

CBS News11-06-2025
Diabetic foot ulcers are a common and major complication for people living with type 1 and type 2 diabetes that can lead to amputation and even death.
When it comes to healing these ulcers, looks can be deceiving. But a new study published by University of Pittsburgh researchers is offering solutions. One of the lead authors told KDKA that what they found could change the definition of wound closure and save lives.
Pitt study could change how wound closure is defined
Jim Bennett, a retired Franklin Park Borough police officer, developed diabetes in his 40s and started getting diabetic foot ulcers. These wounds have high rates of recurrence.
"It does take away from your quality of what you want to do, not really your quality of life, just something ot deal with," Bennett said.
He eventually had several surgeries to amputate six of his toes, including all of them on his left foot.
"I could not continue working because I couldn't wear the uniform shoes, so I had to retire eight months earlier than I had planned," he said.
Bennett's 40-year career in the Franklin Park police force ended in 2014. Now, the 73-year-old said he goes to the wound clinic at UPMC Passavant once a week.
"There are some open wounds that appeared at the bottom of my foot, and that's what's taking so long to heal right now. It starts to close up, then it opens up. And then another infection comes along and starts all over again," Bennett said.
Because of the on-again, off-again wounds and the special boots he has to wear, there are a lot of things Bennett enjoys doing that he can't anymore.
"I've always been pretty active, and I like to do things outside at the home and do things that you can't do anymore. I am hoping when I get out of these boots to be able to do those things again, some of them," said Bennett.
Dr. Chandan Sen, director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh, calls diabetic foot ulcers "invisible wounds." Sen is also a professor in the Department of Surgery at Pitt and the chief scientific officer of Wound Healing Services at UPMC.
He said the diabetic ulcers may appear healed and meet the FDA's definition of wound closure, which is when it's covered by new skin and has not had any discharge for two weeks.
"That definition does not consider the functionality of the skin that just grew back," Sen said.
In a new study with nearly 400 participants, Dr. Sen and his team show it's possible to detect invisible wounds by measuring water loss with a handheld device.
"When we place the pen-like device, it gives us how much water is the body leaking," he said.
"Using this device, you can test the functionality in a matter of five to 10 minutes know whether the skin that is covering the wound is properly functioning or nonfunctioning....and now that we know which wounds are more likely recurr, we need additional care for them so that they stay closed," Dr. Sen added.
He said these findings show the Food and Drug Administration's definition of wound closure needs to be updated.
"Because it is not sufficient to close the wound with the skin, you also need to restore barrier function. That aspect is missing in today's definition of wound closure. This study and studies after this hopefully will go on to make a policy change in how wound closure is defined going forward. And that's a significant contribution to overall care of wounds clinically," Dr. Sen said.
"The goal is to keep on going until we have no amputation," he added.
If you have diabetes and find an ulcer on your foot, even if it's a tiny wound, seek help and see a doctor as soon as possible.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MYOS PET and Leading Veterinarian Urge Action as Weather Extremes Impact Senior Pet Muscle Health
MYOS PET and Leading Veterinarian Urge Action as Weather Extremes Impact Senior Pet Muscle Health

Yahoo

time7 minutes ago

  • Yahoo

MYOS PET and Leading Veterinarian Urge Action as Weather Extremes Impact Senior Pet Muscle Health

CEDAR KNOLLS, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- With climate changes becoming more severe, veterinary sports medicine and rehabilitation expert Dr. Kelly Fishman, DVM, CVA, CCRT, warns that summer heat waves and winter freezes are silently accelerating muscle loss in senior pets. But, MYOS PET, a science-based muscle health brand, is helping veterinarians address the issue with nutrition-based solutions like Fortetropin®. 'Just like humans, dogs and cats naturally lose muscle mass as they age,' said Fishman, founder of Strut Animal Mobility Specialists and veterinary advisory board member at MYOS PET. 'But aging isn't the only cause—extended periods of inactivity, especially when pets are kept indoors due to extreme heat or cold, can also accelerate muscle loss.' To help prevent weather-related muscle loss and take proactive steps to support muscle health year-round, Fishman encourages pet parents to adjust exercise routines based on seasonal conditions. During hot summer months, dogs should be walked in the early morning or late evening, when temperatures are cooler. Choosing shaded, grassy areas can help reduce overheating and protect sensitive paw pads. On especially hot days, low-impact activities like swimming in a pool or creating an indoor obstacle course can keep pets moving without risking heat stress. In colder months, Fishman says preparing your dog's body for movement is important. Gentle spine stretching before going outside can help warm up muscles and reduce the risk of injury. Creating a winter-friendly exercise plan using resistance bands or core-strengthening exercises on stability balls helps improve balance and maintain muscle health in all seasons, Fishman recommends incorporating MYOS PET into treatment plans for aging and recovering pets. MYOS PET contains Fortetropin, a natural bioactive compound derived from fertilized raw egg yolk that has been shown to support muscle protein synthesis and reduce muscle loss.'I recommend MYOS PET with Fortetropin for many of the dogs I rehab and I use it on my own senior cat to improve his energy and mobility,' said Fishman. 'Fortetropin is one of the few tools we have that's backed by credible research and helps preserve muscle through every season.' In studies, Fortetropin has demonstrated benefits for both dogs and cats, including increased lean muscle mass and improved recovery after orthopedic surgery, without adverse side effects. It is increasingly being used by veterinarians to support long-term mobility in senior, post-surgical, and sedentary pets. A study published in Frontiers in Veterinary Science involving working dogs found that a rigorous endurance training program, including treadmill running and obstacle courses, conducted during the winter and spring months not only enhanced the dogs' athletic performance, but also improved their ability to tolerate heat in the summer. Researchers observed that the trained dogs developed a kind of internal 'thermostat,' enabling their bodies to activate cooling mechanisms, such as panting, more efficiently and at lower temperatures. This helped keep them cooler and reduced the risk of heat-related stress during warmer conditions. Fishman says the findings suggest that staying active does more than just build muscle and strength, it can also condition a dog's body to better regulate temperature, ultimately improving performance and safety during periods of extreme heat. For more information on maintaining your pet's muscle health year-round visit Photos accompanying this announcement are available at CONTACT: Media Contact: Amy Summers 212-757-3419 | amy@ Pitch Publicity®Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Stroke Diagnostic and Therapeutic Market to Hit Valuation of US$ 81.68 Billion By 2033
Stroke Diagnostic and Therapeutic Market to Hit Valuation of US$ 81.68 Billion By 2033

Yahoo

time38 minutes ago

  • Yahoo

Stroke Diagnostic and Therapeutic Market to Hit Valuation of US$ 81.68 Billion By 2033

The stroke market is experiencing unprecedented growth, fueled by intense corporate investment and disruptive technologies like AI. This surge is rapidly advancing diagnostic speed and therapeutic options, fundamentally transforming the entire continuum of patient care. Chicago, July 17, 2025 (GLOBE NEWSWIRE) -- The global stroke diagnostic and therapeutic market was valued at US$ 42.07 billion in 2024 and is expected to reach US$ 81.68 billion by 2033, growing at a CAGR of 7.65% during the forecast period 2025–2033. Within the stroke diagnostic and therapeutic market, the segment for endovascular therapy (EVT) is experiencing unprecedented growth, solidified by a wave of compelling clinical evidence. A significant recent development involves a standardized, image-guided neurosurgical technique for clot removal in intracerebral hemorrhage, which has been shown to substantially improve patient outcomes; remarkably, the number needed to treat to achieve functional independence with this method is just eight patients. For ischemic stroke patients with large vessel occlusion and an extensive ischemic core, the benefits of EVT are now undisputed, with five randomized controlled trials confirming less disability compared to medical management alone. Request Sample Copy: The positive data is quantifiable, showing that for every 100 patients treated with EVT, an additional 17 achieve a better functional outcome and six more lives are saved. Further refining the treatment protocol, a post hoc analysis has revealed that administering intravenous thrombolysis (IVT) less than 140 minutes before EVT significantly boosts positive results. This efficacy extends to more distal blockages, as highlighted by a French registry on distal M2 MCA occlusions which reported successful reperfusion in 85% of patients undergoing EVT. The therapeutic landscape is also shifting, as five phase 3 trials have now established the noninferiority of tenecteplase when compared directly to alteplase, a change poised to significantly impact the stroke diagnostic and therapeutic market. Key Findings in Stroke Diagnostics and Therapeutics Market Market Forecast (2033) US$ 81.68 billion CAGR 7.65% Largest Region (2024) North America (29%) By Type Diagnostics (56.31%) By Application Ischemic Stroke (62.27%) Top Drivers Increasing global prevalence of stroke and associated risk factors Technological advancements in diagnostic imaging and minimally invasive therapies Rising healthcare expenditure and awareness of early stroke diagnosis Top Trends Growing adoption of artificial intelligence in stroke diagnosis Shift towards minimally invasive endovascular treatment procedures Expansion of telemedicine and remote tele-stroke services Top Challenges Stringent regulatory approvals for new devices and therapeutics Pharmaceutical Pipeline for Ischemic Stroke Explodes with Over 200 Novel Drugs The pharmaceutical pipeline is a highly competitive and lucrative corner of the stroke diagnostic and therapeutic market. The sheer scale of this research and development effort is immense, with over 50 companies actively working on more than 55 distinct pipeline drugs. In total, the current ischemic stroke pipeline features an impressive 202 drugs in various stages of development from 182 different companies and institutions, a testament to the vibrancy of the stroke diagnostic and therapeutic market. The preclinical stage is currently the most active area of innovation, with 76 unique drugs being investigated, signaling a robust future for novel therapies. Several candidates are progressing through the clinical trial process, generating significant market anticipation. Among them, JX10, a promising drug with both thrombolytic and anti-inflammatory properties, is currently in Phase II trials, while the neuroprotective agent Nelonemdaz has advanced to the critical Phase III stage. Adding to the momentum, an investigational drug known as AB126 is scheduled to commence a Phase I/II clinical trial in the first half of 2024. This wave of innovation is already impacting clinical practice, as highlighted by NICE's official recommendation in July 2024 to use tenecteplase for acute ischaemic stroke in adults. New Surgical and Drug Therapies Redefine Hemorrhagic Stroke Intervention Strategies Progress in managing hemorrhagic stroke is accelerating, creating new opportunities within the stroke diagnostic and therapeutic market. A landmark 2024 study has demonstrated for the first time the benefit of a standardized, image-guided microsurgical technique for clot removal over medical management alone, specifically leading to better six-month outcomes for patients with lobar hemorrhage. On the pharmaceutical front, for patients experiencing major intracranial bleeding related to Factor Xa inhibitors, the reversal agent andexanet alfa achieved hemostasis in a significant 67% of patients in a key trial. Another major advancement is seen in the treatment of subacute and chronic subdural hematoma, where middle meningeal artery embolization used as an adjunct to surgery drastically reduces the likelihood of recurrence. The recurrence rate within 90 days plummeted to just 4.1% in the group receiving embolization with surgery, compared to 11.3% in the surgery-only group. Alongside these interventions, research confirms that intensive blood pressure reduction in the initial stages of intracerebral hemorrhage effectively lessens the absolute growth of hematomas. Despite these gains, the precise role of surgery in hemorrhagic stroke continues to be a subject of intense research, shaping the future of the stroke diagnostic and therapeutic market. Telestroke Networks Emerge as a Critical Solution to Access-to-Care Gaps Telemedicine is proving to be an indispensable tool, expanding the reach of the stroke diagnostic and therapeutic market to underserved populations. The integration of telestroke platforms facilitates immediate remote consultations and allows for the continuous monitoring of patients, which is particularly crucial for improving care access in regions with limited specialized healthcare resources. The need for such systems is underscored by persistent gaps in public awareness; one survey revealed that only 38% of people could identify all major stroke symptoms and knew to call emergency services. This knowledge deficit contributes to treatment delays, as patients who arrive at an emergency room within three hours of their first symptoms often experience significantly less disability three months later. A nationwide study in the US highlighted the scale of this problem, finding that 54% of stroke patients arrived at a hospital more than two hours after their symptoms began, with these critical delays being more common among older, female, and Black patients. Telestroke networks directly address this challenge by providing a vital bridge, enabling rapid remote evaluation by neurologists to expedite life-saving treatment decisions. Technology-Infused Rehabilitation Creates New Pathways for Long-Term Stroke Recovery The field of stroke rehabilitation is being reinvented, representing a rapidly evolving segment of the stroke diagnostic and therapeutic market. Robotic devices are becoming central to this new paradigm, delivering the kind of highly targeted and intensive therapy needed to help patients regain critical motor function. A significant market development is the Vivistim Paired VNS System, a surgically implanted device that recently gained FDA approval for chronic stroke patients. This innovative vagus nerve stimulation system is specifically designed for individuals with moderate to severe upper arm impairment six months to over 20 years after their stroke. While the surgical procedure to implant the device has been established for decades, its application for stroke recovery is a novel and promising approach. Following implantation, patients engage in a rigorous six-week intensive rehabilitation program. This is complemented by the growing use of wearable technology, such as inertial measurement units and electromyography sensors, which allow for highly tailored assessments and therapies. Concurrently, home-based rehabilitation programs are gaining significant traction, offering patients a more convenient and cost-effective path to recovery. Advanced Neuroimaging Technologies Provide Unprecedented Clarity in Stroke Diagnosis The diagnostic imaging sector of the stroke diagnostic and therapeutic market is advancing rapidly, with new technologies providing unparalleled insights into the brain to facilitate earlier and more precise diagnoses. High-resolution magnetic resonance imaging (MRI) and computed tomography (CT) scans remain the cornerstones for the early detection and exact localization of stroke lesions. While non-contrast CT is still a primary modality for the initial evaluation of a suspected stroke, recent advances have boosted its overall diagnostic sensitivity to 64% and its specificity to 85%. A major technological leap occurred in December 2023 with the unveiling of the NAEOTOM Alpha, a pioneering diagnostic imaging system poised to set new standards in the field. Simultaneously, automated stroke detection software from leading companies like Brainomix, RapidAI, and is achieving widespread adoption and gaining significant market traction. The integration of artificial intelligence with this imaging data is a game-changer; it can now help clinicians predict the final infarct volume and accurately assess the risk of hemorrhagic transformation. Operator and Hospital Experience Emerge as Key Drivers of Patient Outcomes The correlation between procedural volume and patient outcomes is becoming a critical point of analysis for stakeholders in the stroke diagnostic and therapeutic market. A comprehensive study involving over 3,000 patients revealed a clear benefit associated with experienced clinicians; it found that higher proceduralist volume, defined as performing 18 or more endovascular therapies per year, was directly associated with reduced in-hospital mortality. The data showed that the absolute risk of death was 4.8% lower in this high-volume group. Another study, however, observed a paradoxical relationship where higher-volume hospitals had worse outcomes, a finding likely attributable to these centers treating a greater proportion of severe and complex cases. This was supported by an analysis where the odds of in-hospital mortality actually increased in higher-volume quartiles. A snapshot from Florida in 2019 showed that of the 297 hospitals, 105 performed mechanical thrombectomy. Among these, 54 were classified as high-volume centers (≥15 MTs/year), with a median of 59.5 cases, compared to a median of just two cases at low-volume hospitals. Stroke's Staggering Global Impact Drives Demand for Innovative Care Solutions Stroke persists as a formidable global health crisis, which in turn fuels the immense global stroke diagnostic and therapeutic market. In 2021 alone, there were 93.8 million stroke survivors and 11.9 million new cases, highlighting the immense scale of the issue. The global cost of stroke is now estimated to be over US$890 billion, placing an enormous economic burden on healthcare systems. Ischemic stroke was the predominant type, accounting for 65.3% of all new strokes in 2021, with a slightly higher incidence among males (52.6%). There are significant regional disparities in both incidence and mortality, revealing inequities in access to care. The lowest age-standardized stroke incidence was observed in Luxembourg (57.7 per 100,000), while the Solomon Islands faced the highest rate (355.0 per 100,000). Similarly, Singapore reported the lowest stroke death rate at 14.2 per 100,000, which stands in stark contrast to North Macedonia, the country with the highest mortality rate at 277.4 per 100,000, illustrating the urgent need for globally accessible and effective solutions from the stroke diagnostic and therapeutic market. Tailor This Report to Your Specific Business Needs: Expanding Therapeutic Windows for Intervention Offer Hope for More Patients Recent clinical research is fundamentally challenging and expanding the traditionally accepted timeframes for effective stroke intervention, a development with profound implications for the stroke diagnostic and therapeutic market. The CT for Late Endovascular Reperfusion (CLEAR) study, which enrolled 2,451 patients, was designed specifically to assess the benefits of EVT within an extended time window, suggesting that even patients with a large ischemic core may still benefit. This is reinforced by a propensity score-matched analysis which found that approximately one-third of large vessel occlusion patients with persistent deficits beyond the 16-hour mark still met the stringent criteria for late-window trials like DAWN or DEFUSE 3. When EVT was performed in these late-presenting patients, it resulted in 11.08-fold higher odds of achieving a good functional outcome. These findings add urgency to the treatment process, as demonstrated by foundational studies like MR CLEAN, which showed that every single hour of delay in achieving reperfusion led to a 7.7% decreased probability of the patient regaining functional independence. Likewise, the REVASCAT trial quantified the cost of delay, showing a 26% decrease in the likelihood of a favorable outcome for every 30-minute delay in reperfusion. Top Companies in Stroke Diagnostic and Therapeutic Market Abbott Laboratories Boston Scientific Corporation Cerebrotech Medical Systems, Inc. Cordis Corporation GE Healthcare Genentech Inc. Gowerlabs Hyperfine MRI Koninklijke Philips N.V. Medfield Diagnostics Medtronic plc. Merck & Co., Inc. Neural Analytics NIRX Samsung Neurologica Siemens AG Stryker Corporation Other Prominent Players Market Segmentation Overview By Type Diagnostics Magnetic Resonance Imaging (MRI) Computed Tomography Scan (CT scan) Electrocardiography Carotid Ultrasound Cerebral Angiography Others Therapeutics Tissue Plasminogen Activator Antiplatelet Antihypertensive Anticoagulant By Application Hemorrhagic Stroke Ischemic Stroke By Region North America Europe Asia Pacific Middle East Africa South America Want Deeper Insights? Book a Free Call with an Expert: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

More than 67,000 cases of Power Stick deodorant recalled nationwide
More than 67,000 cases of Power Stick deodorant recalled nationwide

Yahoo

time38 minutes ago

  • Yahoo

More than 67,000 cases of Power Stick deodorant recalled nationwide

More than 67,000 cases of Power Stick deodorants have been recalled for not meeting quality and safety standards. A.P. Deauville, a health and beauty product manufacturer in Pennsylvania, issued a recall for 67,214 cases of Power Stick roll-on deodorant on July 10. The products were recalled for cGMP deviations, which are deviations from established regulations outlined by the Food and Drug Administration (FDA)-enforced Current Good Manufacturing Practices. The recall does not specify a remedy for consumers or which regulations were missed. A.P. Deauville did not immediately respond for comment about the recall when contacted by USA TODAY on Thursday, July 17. What products are listed in the recall? Can't see the table in your browser? Visit Where were the recalled products sold? According to the recall, the Power Stick deodorants were sold nationwide. The deodorants are available for purchase from major retailers such as Walmart and Amazon. What to do with the recalled Power Stick deodorant? The FDA usually recommends discarding recalled products and contacting the manufacturer with any questions you may have. Greta Cross is a national trending reporter at USA TODAY. Story idea? Email her at gcross@ This article originally appeared on USA TODAY: More than 67,000 cases of Power Stick deodorant recalled

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store